Aptevo Therapeutics (NASDAQ:APVO) Announces Quarterly Earnings Results

Share on StockTwits

Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01, Fidelity Earnings reports. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%. The firm had revenue of $9.01 million for the quarter, compared to the consensus estimate of $8.05 million.

Shares of APVO stock traded up $0.04 during trading hours on Friday, reaching $0.65. The company had a trading volume of 727,500 shares, compared to its average volume of 519,858. The company has a 50 day moving average of $0.61 and a 200 day moving average of $0.75. Aptevo Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.65. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.63 and a quick ratio of 2.21. The firm has a market cap of $29.33 million, a price-to-earnings ratio of -0.27 and a beta of 2.44.

A number of research analysts have recently weighed in on the company. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 16th. Finally, Piper Jaffray Companies cut their price target on Aptevo Therapeutics from $4.50 to $3.00 in a research note on Friday, October 4th.

In other Aptevo Therapeutics news, Director Fuad El-Hibri acquired 100,000 shares of Aptevo Therapeutics stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $0.76 per share, for a total transaction of $76,000.00. Following the purchase, the director now directly owns 1,124,536 shares in the company, valued at approximately $854,647.36. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 11.74% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Article: Ex-Dividend

Earnings History for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.